XTL Biopharmaceuticals (NASDAQ:XTLB) Share Price Crosses Below Two Hundred Day Moving Average – Time to Sell?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.67 and traded as low as $2.43. XTL Biopharmaceuticals shares last traded at $2.4550, with a volume of 1,829 shares changing hands.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

XTL Biopharmaceuticals Stock Performance

The stock has a market cap of $5.82 million, a PE ratio of -3.84 and a beta of 1.38. The company’s 50-day moving average price is $2.77 and its 200 day moving average price is $2.67.

XTL Biopharmaceuticals (NASDAQ:XTLB) last issued its quarterly earnings data on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The firm had revenue of ($0.26) million for the quarter.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.